Poster: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody

Check out our poster on a discovery journey in identifying a dual-antagonistic mab for an IO check point receptor utilizing Curia proprietary platform technology including pentamice for maximum antibody diversity, TunaCHO for high yield transient expression, in silico humanization, epitope binning, hybridoma antibody discovery, cell based bioassay. All capabilities and expertise under one-stop shop for your next biologics discovery.

(Click on poster image for access to full document)

Visit this page for a deeper understanding of our Antibody Discovery & Engineering Services.

Supplemental Information:
Whitepaper: Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery

Fact Sheet: PentaMice – Own your molecules:Therapeutic antibody discovery

Brochure: TunaCHO℠ Platform for Transient Protein & Antibody Production

Brochure: Introduction to hybridoma technologies for antibody discovery

Brochure: Antibody discovery & engineering services

Webinars:
#102: Discovery of Potent, Functional Antibodies Using Hybridoma & Phage Display Platforms Webinar – YouTube
#111: PentaMice™: A Unique Approach to Achieve Maximum Plasma Titers for Antibody Discovery Webinar – YouTube
#115: LakePharma’s Coronavirus Spike Protein Antibodies Webinar – YouTube